TCWP’s Travere Therapeutics TVTX Stock Holding History

TCWP’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-91	Closed	-$2K	–	1633
2022 Q1	$2K	Buy	+91	New	+$2.42K	﹤0.01%	1393

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCWP's TVTX Position: Q2 2022 in Review

TCWP sold out of Travere Therapeutics (TVTX) in Q2 2022, closing a stake of 91 shares — an estimated $2K sold.

TCWP first reported a position in TVTX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q2 2022.

TCWP reported no remaining Travere Therapeutics position as of Q2 2022 after selling out during the quarter.
TCWP sold 91 Travere Therapeutics shares in Q2 2022, an estimated $2K.
TCWP first reported a position in Travere Therapeutics in Q1 2022 and held it in 1 quarter.
TCWP's Travere Therapeutics position peaked at $2K in Q1 2022.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.